Evidence map›Paper›PMID 24227693›Full record

ArticleCytometry. Part B, Clinical cytometry2014

A prospective multicenter study of paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure.

Azra Raza, Farhad Ravandi, Anjay Rastogi, Jeffrey Bubis, Seah H Lim, Ilene Weitz, Hugo Castro-Malaspina, Naomi Galili, Rony Abou Jawde, Andrea Illingworth

Open access · greenAbstract readMulticenter Study
In one paragraph

Article in Cytometry. Part B, Clinical cytometry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 64 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. A Prospective, Cross Sectional Study of PNH Clone in MDS Patients Using High Sensitivity Flowcytometry: A Single Center Experience.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2020
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 8 institutions in 1 country.

Azra RazaDepartment of Medicine, Columbia University, New York, New York.
Farhad Ravandi
Anjay Rastogi
Jeffrey Bubis
Seah H Lim
Ilene Weitz
Hugo Castro-Malaspina
Naomi Galili
Rony Abou Jawde
Andrea Illingworth
Columbia University · USColumbia University Irving Medical Center · USFlorida Cancer Specialists & Research Institute · USHeartland Regional Medical Center · USMemorial Sloan Kettering Cancer Center · USTexas Oncology · USThe University of Texas MD Anderson Cancer Center · USUniversity of Southern California · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

backgroundParoxysmal nocturnal hemoglobinuria (PNH), a rare clonal hematopoietic stem cell disorder, is characterized by chronic, uncontrolled complement activation leading to intravascular hemolysis and an inflammatory prothrombotic state. The EXPLORE study aimed to determine the prevalence of undiagnosed PNH in patients with aplastic anemia (AA), myelodysplastic syndrome (MDS), and/or other bone marrow failure (BMF) syndromes and the effect of PNH clone size on hemolysis.

methodsPatients, selected from medical office chart reviews, had blood samples collected for hematologic panel testing and for flow cytometry detection of PNH clones.

resultsGranulocyte PNH clones ≥ 1% were detected in 199 of all 5,398 patients (3.7%), 93 of 503 AA patients (18.5%), 50 of 4,401 MDS patients (1.1%), and 3 of 130 other BMF patients (2.3%). Higher-sensitivity analyses detected PNH clones ≥ 0.01% in 167 of 1,746 patients from all groups (9.6%) and in 22 of 1,225 MDS patients (1.8%), 116 of 294 AA patients (39.5%), and four of 54 other BMF patients (7.8%). Among patients with PNH clones ≥ 1%, median clone size was smaller in patients with AA (5.1%) than in those with MDS (17.6%) or other BMF (24.4%), and the percentage of patients with lactate dehydrogenase levels (a marker for intravascular hemolysis) ≥ 1.5 × upper limit of normal was smaller in patients with AA (18.3%) than in those with MDS (42.0%).

conclusionsThese results confirm the presence of PNH clones in high-risk patient groups and suggest that screening of such patients may facilitate patient management and care.

Indexed as

AdolescentAdultAgedAged, 80 and overAnemia, AplasticBone MarrowChildClone CellsFemaleFlow CytometryGranulocytesHemoglobinuria, ParoxysmalHemolysisHumansImmunophenotypingL-Lactate DehydrogenaseL-Lactate Dehydrogenasebone marrow dysfunctionclinical trialflow cytometryhematologyparoxysmal nocturnal hemoglobinuria

Identifiers

PMID24227693
PMCPMC5594745
OpenAlexW1817019822

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.